Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai’s Lenvatinib Gains Priority Review | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Eisai’s Lenvatinib Gains Priority Review

For the potential treatment of unresectable advanced or metastatic renal cell carcinoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai’s sNDA for lenvatinib has been accepted for Priority Review by the FDA for the potential treatment of unresectable advanced or metastatic renal cell carcinoma (RCC) in combination with everolimus following one prior vascular endothelial growth factor (VEGF)-targeted therapy. The FDA had previously granted lenvatinib Breakthrough Therapy designation for this indication.
 
Priority Review is intended for drugs that treat serious conditions and, if approved, would provide a significant improvement in safety or effectiveness. The prognosis for patients with advanced renal cell carcinoma is poor and additional treatment options are needed.
 
Lenvatinib is a multiple receptor tyrosine kinase inhibitor sold as LENVIMA, and is indicated for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics